List of the Top AI Science Software for Government in 2026 - Page 2

LeapSpace is a cutting-edge research platform powered by AI, developed by Elsevier, aimed at enhancing the transition from research inquiries to innovative solutions for academic and corporate researchers within a secure environment. This pioneering workspace combines responsible artificial intelligence with one of the most extensive collections of peer-reviewed scientific literature, featuring millions of full-text articles and over 100 million abstracts from numerous publishers, thereby ensuring that researchers base their findings on reliable evidence rather than unverified online sources. Users can engage with complex research topics through natural-language queries, receiving structured, cited responses that ease the evaluation of primary sources and the confirmation of findings. Additionally, LeapSpace is tailored to support the entire research process, allowing users to brainstorm ideas, organize their projects, analyze existing literature, compare different studies, and create comprehensive reports that reveal trends, inconsistencies, and gaps in ongoing research efforts. This integrated approach not only boosts research productivity but also enhances users' comprehension of their disciplines, ultimately fostering a more informed academic and corporate community. Hence, LeapSpace stands as a vital tool for those seeking to elevate their research endeavors.

Osmosis AI acts as an engaging study assistant that is seamlessly integrated into the Osmosis learning platform, designed to help medical and health professional students understand, review, and reinforce complex subjects through a combination of AI-generated explanations and trusted educational materials. By merging Elsevier's extensive library of peer-reviewed medical textbooks and resources with the visual learning techniques of Osmosis, it delivers responses that are evidence-based, well-cited, and connected to relevant videos, diagrams, and study aids. This cutting-edge tool enables students to ask questions in real-time without interrupting their study flow, providing clear explanations in simple language along with direct references to the original sources for verification. In contrast to many platforms that rely on publicly available web data, Osmosis AI operates within a carefully curated "walled garden" of selected medical content, which reduces the likelihood of inaccuracies and ensures compliance with the educational standards for teaching and assessment within the medical domain. Consequently, this approach allows students to engage in a more concentrated and trustworthy learning experience, ultimately deepening their comprehension of challenging topics. Moreover, the design of Osmosis AI encourages continuous interaction, fostering a dynamic educational environment that caters to the diverse needs of learners.

ResoluteAI provides a robust platform that enables users to conduct simultaneous searches across a wide range of aggregated scientific, regulatory, and business databases. Its interactive analytics and downloadable visualizations empower users to establish connections that could lead to groundbreaking discoveries. Nebula, the enterprise search solution from ResoluteAI designed specifically for the scientific sector, harnesses structured metadata along with advanced AI tools to enhance institutional knowledge. This innovative system integrates a variety of technologies, including natural language processing, optical character recognition, image recognition, and transcription, facilitating the discovery and retrieval of proprietary information with ease. By using Nebula, researchers can uncover the hidden value in their studies, experiments, market insights, and acquired assets. With the advantage of structured metadata from unstructured text, users gain access to features such as semantic expansion, conceptual search, and document similarity search, ensuring a thorough investigation of their data. This groundbreaking platform revolutionizes the way scientific information is accessed and leveraged, leading to improved research outcomes and fostering collaboration within the scientific community. Moreover, its user-friendly interface and powerful search capabilities make it an essential tool for researchers aiming to push the boundaries of knowledge.

ScienceDesk's data automation revolutionizes the incorporation of artificial intelligence in materials science. This innovative tool offers teams a practical means to consistently adopt and apply the most recent AI algorithms in their everyday tasks. It includes customizable features, universal identifiers, QR codes, and a powerful search engine that links sample data to experimental outcomes. As a pioneering platform, ScienceDesk promotes collaboration among scientists and engineers, enabling them to interact with and derive insights from their experimental data. Nevertheless, the full capabilities of this resource remain largely unexploited due to the variety of data formats and the dependence on experts for manually extracting specific information. The ScienceDesk research data management system tackles this issue by integrating documentation with data analysis within a well-structured data framework. Our algorithms give researchers and scientists complete control over their data, allowing them to not only exchange datasets but also to share their analytical knowledge, thereby nurturing a more collaborative atmosphere in research. Additionally, ScienceDesk plays a crucial role in enhancing data accessibility, sparking innovative methodologies in scientific exploration. Ultimately, the platform encourages a new wave of collaborative innovation in the materials science community.

Optimize the entire selection process for reagents and model systems to eliminate inefficiencies and reduce errors that can result in costly experimental setbacks. By condensing the decision-making timeframe from the usual 12 weeks to a mere 30 seconds, project timelines can be significantly shortened. This strategy not only minimizes direct expenses associated with consumables but also has the capacity to generate substantial annual savings. In addition, it supports the organizational mission by allowing scientists to reclaim precious research time. Experience concrete business benefits from AI through a solution that is both proven and ready for implementation. Over 41,200 scientists, representing 15 of the top 20 pharmaceutical companies and more than 4,450 academic institutions, rely on BenchSci’s AI-Assisted Antibody Selection to design more effective experiments while achieving significant reductions in hard costs. It’s crucial to recognize that antibodies account for only 40-50% of the reagent-related failures. Gain access to a wealth of experimental evidence, an extensive catalog of reagents and model systems, and independent validations, all within a single intuitive interface. Leverage real-world experimental data sourced from 11.2 million scientific publications, including those often not publicly available, for a comprehensive approach to research. This cutting-edge methodology equips researchers with the tools necessary to make swift and informed decisions, ultimately transforming the landscape of scientific experimentation. By streamlining processes and enhancing data accessibility, the opportunity for breakthroughs in research becomes significantly more attainable.

At Iris.ai, we have dedicated the past six years to developing an award-winning AI engine that excels in comprehending scientific texts. Our state-of-the-art algorithms for text similarity, extraction of tabular data, learning domain-specific entity representations, and entity disambiguation and linking rank among the finest globally. Additionally, our machine constructs an extensive knowledge graph that encompasses all entities and their interconnections, enabling users to learn from it, utilize it, and also provide feedback to enhance the system further. The Iris.ai Researcher Workspace offers a versatile suite of tools that enables users to tackle projects from multiple perspectives. Its modules feature content-driven exploratory searches, analytical assessments of document collections, systematic extraction and organization of data points, automated summarization of various documents, and highly effective filters based on context descriptions, machine analyses, or targeted data points and entities. Furthermore, the Iris.ai engine for scientific text understanding is a robust interdisciplinary platform that can be automatically fine-tuned for specific research domains, allowing for a deeper machine comprehension without the need for human training or annotation, ultimately streamlining the research process.

Recursion is a pioneering TechBio company reimagining drug discovery through the integration of biology, artificial intelligence, and large-scale data. Founded more than ten years ago, Recursion introduced a novel approach that uses cellular imaging to train AI models to understand disease mechanisms. The company’s mission is to reduce the high failure rate of traditional drug development by uncovering deeper biological insights. At the core of its work is the Recursion OS, a drug discovery and development platform that unifies data, machine learning, and automated experimentation. Recursion has built one of the world’s largest proprietary biological and chemical datasets, spanning phenomics, transcriptomics, proteomics, and patient data. Its automated wet labs generate millions of experiments weekly, creating a continuous feedback loop that improves model performance. This system enables rapid identification of new drug targets and optimized molecule design. Recursion’s pipeline includes multiple programs addressing aggressive cancers and rare diseases with significant unmet needs. The company partners with pharmaceutical leaders, computational technology providers, and data innovators to extend its impact. With BioHive-2, a powerful supercomputer built with NVIDIA, Recursion processes massive datasets at unprecedented speed. These capabilities allow the company to move candidates faster from discovery to clinical trials. Overall, Recursion is focused on delivering better medicines to patients through AI-driven precision and scale.

Proteins are extraordinary and intricate entities that form the bedrock of biological processes not just within your own body, but across all living organisms on our planet. They are essential to the very fabric of life. Currently, there are roughly 100 million identified unique proteins, with fresh discoveries occurring each year. Each of these proteins has a unique three-dimensional structure that influences its function and purpose. Nonetheless, pinpointing the exact structure of a protein is frequently a resource-intensive task, leading to only a limited number of proteins having their precise 3D configurations mapped by researchers. Tackling this expanding challenge and creating techniques to forecast the structures of numerous unidentified proteins could greatly improve our capacity to fight diseases and accelerate the development of innovative drugs. Furthermore, such breakthroughs might shed light on the fundamental nature of life itself, paving the way for transformative advancements in our comprehension of biological systems and yielding significant progress in the fields of medicine and biotechnology. The potential implications of these developments could be profound, influencing not only our health but also our understanding of the mechanisms that sustain life.

BioNeMo is a cloud-based platform designed for drug discovery that harnesses artificial intelligence and employs NVIDIA NeMo Megatron to enable the training and deployment of large biomolecular transformer models at an impressive scale. This service provides users with access to pre-trained large language models (LLMs) and supports multiple file formats pertinent to proteins, DNA, RNA, and chemistry, while also offering data loaders for SMILES to represent molecular structures and FASTA for sequences of amino acids and nucleotides. In addition, users have the flexibility to download the BioNeMo framework for local execution on their own machines. Among the notable models available are ESM-1, which is based on Meta AI’s state-of-the-art ESM-1b, and ProtT5, both fine-tuned transformer models aimed at protein language tasks that assist in generating learned embeddings for predicting protein structures and properties. Furthermore, the platform will incorporate OpenFold, an innovative deep learning model specifically focused on forecasting the 3D structures of new protein sequences, which significantly boosts its capabilities in biomolecular exploration. Overall, this extensive array of tools establishes BioNeMo as an invaluable asset for researchers navigating the complexities of drug discovery in modern science. As such, BioNeMo not only streamlines research processes but also empowers scientists to make significant advancements in the field.

Clara offers advanced tools and pre-trained AI models that are facilitating remarkable progress across a variety of industries, including healthcare technologies, medical imaging, pharmaceutical innovation, and genomic exploration. Explore the detailed workflow involved in the creation and application of medical devices through the Holoscan platform. Utilize the Holoscan SDK to design containerized AI applications in partnership with MONAI, thereby improving deployment capabilities in cutting-edge AI devices with the help of NVIDIA IGX developer kits. Additionally, the NVIDIA Holoscan SDK features acceleration libraries specifically designed for the healthcare sector, along with pre-trained AI models and sample applications that cater to computational medical devices. This strategic blend of tools not only promotes innovation and efficiency but also empowers developers to address intricate challenges within the medical landscape. As a result, the framework provided by Clara positions professionals at the forefront of technological advancements in healthcare.

NVIDIA® Parabricks® is distinguished as the only comprehensive suite of genomic analysis tools that utilizes GPU acceleration to deliver swift and accurate genome and exome assessments for a variety of users, including sequencing facilities, clinical researchers, genomics scientists, and developers of high-throughput sequencing technologies. This cutting-edge platform incorporates GPU-optimized iterations of popular tools employed by computational biologists and bioinformaticians, resulting in significantly enhanced runtimes, improved scalability of workflows, and lower computing costs. Covering the full spectrum from FastQ files to Variant Call Format (VCF), NVIDIA Parabricks markedly elevates performance across a range of hardware configurations equipped with NVIDIA A100 Tensor Core GPUs. Genomics researchers can experience accelerated processing throughout their complete analysis workflows, encompassing critical steps like alignment, sorting, and variant calling. When users deploy additional GPUs, they can achieve near-linear scaling in computational speed relative to conventional CPU-only systems, with some reporting acceleration rates as high as 107X. This exceptional level of efficiency establishes NVIDIA Parabricks as a vital resource for all professionals engaged in genomic analysis, making it indispensable for advancing research and clinical applications alike. As genomic studies continue to evolve, the capabilities of NVIDIA Parabricks position it at the forefront of innovation in this rapidly advancing field.

Precision, efficiency, and reliability characterize the new era of integration between generative AI and the biopharmaceutical sector. This innovative technology simplifies the challenging processes involved in collecting, organizing, and analyzing large volumes of data. You can achieve critical insights with confidence every single time. Our AI-powered platform optimizes data management and validation, allowing you to maintain organized workflows with ease. You can gather, process, and confirm your data from a unified interface. Effortlessly navigate through both public and private databases by utilizing specific drug attributes. Classify drugs and clinical trials according to detailed patient demographics, making it easier to retrieve vital information in clear terms. Enhance your conclusions by connecting your results back to their original sources. Focus on extracting meaningful outputs from your data while avoiding the cumbersome manual sorting tasks. With our cutting-edge language models, researchers can perform asset evaluations approximately 4.8 times faster than conventional approaches. You will have access to a vast repository of over 38 million scientific papers, conference proceedings, and clinical trial information. This platform ensures you have all necessary data readily available, facilitating timely and informed decisions. Furthermore, our system is designed to adapt to your specific requirements, further enriching the research process and driving innovation in the industry. By leveraging these advancements, you can truly transform your approach to biopharmaceutical research.

Cure AI is an innovative medical research platform that leverages artificial intelligence to provide users with access to a vast collection of over 26 million scientific articles from PubMed. Utilizing advanced natural language processing, the platform allows users to ask research-related queries in a conversational style, which it effectively interprets to deliver precise and pertinent results. Additionally, it features advanced search filters, enabling users to refine their searches based on criteria such as publication date, journal, and other relevant factors to meet their specific research needs. Furthermore, Cure AI assesses the quality and importance of evidence by considering metrics like h5-index, citation counts, and publication types, ensuring that users receive only the most reliable and relevant information. The platform also improves the user experience by facilitating seamless transitions between AI-generated insights and the original research articles, thereby making literature review and analysis more efficient. In addition, it includes handy citation tools that allow users to quickly copy or share references with a simple click, which streamlines the documentation process significantly. With its user-friendly design, Cure AI not only simplifies research but also inspires researchers to pursue new lines of inquiry with greater confidence and ease, enhancing the overall exploration of scientific knowledge.

Biologit offers a wide array of software and services designed to enhance safety surveillance across various industries. At the forefront is their flagship product, biologit MLM-AI, a sophisticated medical literature monitoring system that leverages artificial intelligence for applications both globally and locally. This intuitive, web-based solution is validated for regulatory compliance, significantly boosting efficiency for human and veterinary pharmacovigilance efforts. Key features include integrated search functions and tailored literature screening methodologies, which can improve productivity by as much as 70% with the help of AI. Moreover, it boasts a versatile and validated SaaS framework that complies with GxP standards and adheres to CFR-11 regulations, along with a database that aggregates vital global and local literature while automatically eliminating duplicate articles. In addition to their software, Biologit extends its expertise through consultancy services focused on pharmacovigilance and veterinary pharmacovigilance, reinforcing their dedication to safety across multiple domains. Their continuous drive for innovation and adherence to compliance regulations firmly establishes them as a prominent figure in the industry landscape. This relentless commitment not only enhances their product offerings but also contributes to the overall advancement of safety practices in medical and veterinary fields.

PubHive Navigator represents a cutting-edge software solution that leverages artificial intelligence to improve the effectiveness of scientific literature management and safety protocols for life science entities of all sizes. It offers a robust array of workflow tools that include literature review, curation, annotation, collaborative efforts, search capabilities, reporting, citation management, and oversight of research activities. The platform features AI-enhanced smart workspaces that enable centralized literature management, collaborative writing for research initiatives, and efficient team communication, all while providing integrations for document delivery and reuse rights, along with pre-configured workflows designed for various operational sectors. Additionally, PubHive Navigator seeks to simplify the intricate challenges tied to enterprise-level scientific literature and safety information processing, making it a flexible resource for teams involved in areas such as drug safety and pharmacovigilance, medical affairs, clinical affairs, and research and development. This adaptability not only streamlines operation but also empowers organizations to refine their research workflows and boost productivity across their teams, fostering a more dynamic approach to scientific advancement. Ultimately, the platform's design supports continuous improvement and innovation in life sciences.

Evo 2 is an advanced genomic foundation model that excels in predicting and creating tasks associated with DNA, RNA, and proteins. Utilizing a sophisticated deep learning architecture, it models biological sequences with precision down to single-nucleotide accuracy, demonstrating remarkable scalability in both computational and memory resources as context length expands. The model has been trained on an impressive 40 billion parameters and can handle a context length of 1 megabase, analyzing an immense dataset of over 9 trillion nucleotides derived from diverse eukaryotic and prokaryotic genomes. This extensive training enables Evo 2 to perform zero-shot function predictions across a range of biological types, including DNA, RNA, and proteins, while also generating novel sequences that adhere to plausible genomic frameworks. Its robust capabilities have been highlighted in applications such as the design of efficient CRISPR systems and the identification of potentially disease-causing mutations in human genes. Additionally, Evo 2 is accessible to the public via Arc's GitHub repository and is integrated into the NVIDIA BioNeMo framework, which significantly enhances its availability to researchers and developers. This integration not only broadens the model's reach but also represents a pivotal advancement in the fields of genomic modeling and analysis, paving the way for future innovations in biotechnology.

FutureHouse is a nonprofit research entity focused on leveraging artificial intelligence to propel advancements in scientific exploration, particularly in biology and other complex fields. This pioneering laboratory features sophisticated AI agents designed to assist researchers by streamlining various stages of the research workflow. Notably, FutureHouse is adept at extracting and synthesizing information from scientific literature, achieving outstanding results in evaluations such as the RAG-QA Arena's science benchmark. Through its innovative agent-based approach, it promotes continuous refinement of queries, re-ranking of language models, contextual summarization, and in-depth exploration of document citations to enhance the accuracy of information retrieval. Additionally, FutureHouse offers a comprehensive framework for training language agents to tackle challenging scientific problems, enabling these agents to perform tasks that include protein engineering, literature summarization, and molecular cloning. To further substantiate its effectiveness, the organization has introduced the LAB-Bench benchmark, which assesses language models on a variety of biology-related tasks, such as information extraction and database retrieval, thereby enriching the scientific community. By fostering collaboration between scientists and AI experts, FutureHouse not only amplifies research potential but also drives the evolution of knowledge in the scientific arena. This commitment to interdisciplinary partnership is key to overcoming the challenges faced in modern scientific inquiry.

Zochi distinguishes itself as the pioneering autonomous AI system that can navigate the complete scientific research process, from hypothesis generation to obtaining peer-reviewed publication, while producing innovative results. Unlike earlier systems that were limited to narrow, predefined tasks, Zochi excels in tackling research issues at the forefront of artificial intelligence. Its efficacy is underscored by a series of peer-reviewed publications accepted at the ICLR 2025 workshops, showcasing Zochi's ability to deliver creative and rigorously validated contributions to the field. Additionally, Zochi identified a critical challenge within AI: the phenomenon of cross-skill interference during parameter-efficient fine-tuning, where adapting models for multiple tasks may enhance one capability at the cost of others. To address this issue, Zochi proposed an innovative strategy known as CS-ReFT (Compositional Subspace Representation Fine-tuning), which focuses on modifying representations rather than changing weights. This transformative method could significantly alter the landscape of how AI systems are fine-tuned for various applications, promising to enhance their versatility and performance in real-world scenarios. The implications of Zochi's advancements may extend far beyond academia, influencing practical implementations across numerous sectors.

Sciscoper is an innovative AI-powered research assistant crafted to streamline and accelerate the literature review process for professionals in STEM disciplines, such as researchers, academics, and R&D teams. Researchers often grapple with the overwhelming task of managing vast arrays of scientific papers from diverse sources, making it challenging to extract meaningful insights efficiently. To tackle this problem, Sciscoper employs advanced AI and natural language processing technologies to automatically: - Provide concise summaries of scientific articles and research findings. - Uncover essential insights, concepts, and connections within various documents. - Generate comprehensive literature reviews complete with citations formatted in multiple styles. - Arrange and classify papers into a structured, searchable knowledge repository for easy access. As a result, users can significantly reduce the amount of time dedicated to monotonous reading and note-taking, allowing them to focus more on analyzing results, identifying gaps for future research, and enhancing the body of scientific knowledge. With its ability to redefine the literature review experience, Sciscoper ultimately fosters more productive research endeavors and drives innovation in the scientific community.

Gemini 3, the latest offering from Google DeepMind, sets a new benchmark in artificial intelligence by achieving exceptional reasoning skills and multimodal understanding across formats such as text, images, and videos. Compared to its predecessor, it shows remarkable advancements in key AI evaluations, demonstrating its prowess in complex domains like scientific reasoning, advanced programming, spatial cognition, and visual or video analysis. The introduction of the groundbreaking “Deep Think” mode elevates its performance further, showcasing enhanced reasoning capabilities for particularly challenging tasks and outshining the Gemini 3 Pro in rigorous assessments like Humanity’s Last Exam and ARC-AGI. Now integrated within Google’s ecosystem, Gemini 3 allows users to engage in educational pursuits, developmental initiatives, and strategic planning with an unprecedented level of sophistication. With context windows reaching up to one million tokens and enhanced media-processing abilities, along with customized settings for various tools, the model significantly boosts accuracy, depth, and flexibility for practical use, thereby facilitating more efficient workflows across numerous sectors. This development not only reflects a significant leap in AI technology but also heralds a new era in addressing real-world challenges effectively. As industries continue to evolve, the versatility of Gemini 3 could lead to innovative solutions that were previously unimaginable.

Prism is a next-generation, LaTeX-native workspace created to accelerate everyday scientific writing and collaboration. It provides a single cloud-based environment where researchers can draft, organize, compile, and collaborate without installing or managing local tools. Prism integrates GPT-5.2 directly into the writing process, delivering intelligent assistance for proofreading, citations, formatting, and literature search. The platform supports unlimited collaborators working in real time with instant previews, eliminating common LaTeX workflow bottlenecks. Its project-aware AI understands the full history and structure of a manuscript, enabling precise updates to equations, tables, sections, and references. Built-in LaTeX rendering ensures consistent formatting and immediate feedback during writing. Prism reduces manual cleanup through automated error checking and formatting tools. Researchers can manage unlimited projects with unlimited compile speed and compile time. Advanced features such as image-to-code, voice-to-code, and Zotero synchronization further streamline academic workflows. Prism is designed for long-form, serious scientific writing across disciplines. It supports collaboration at scale without version conflicts or slow iterations. Overall, Prism transforms LaTeX into a modern, AI-powered research workspace.

BenevolentAI is a groundbreaking platform that harnesses the power of artificial intelligence and advanced scientific methodologies to improve the drug discovery process, particularly for challenging diseases, by swiftly analyzing and interpreting vast amounts of biomedical data to generate practical insights more quickly than traditional methods. Through its distinctive Benevolent Platform, the company adeptly combines both structured and unstructured biomedical data—including literature, genomic information, clinical records, and multi-omics—into a comprehensive knowledge graph. This sophisticated structure enables researchers to explore biological systems, develop testable hypotheses, discover new drug targets, and design potential drug candidates with greater assurance and lower chances of failure, thereby revolutionizing the field of medicine development. By pioneering such innovative strategies, BenevolentAI not only enhances the efficiency of pharmaceutical research but also significantly impacts the future of healthcare and treatment options. As a result, BenevolentAI is positioned as a leader in ushering in a transformative phase within the pharmaceutical sector.

Gemini for Science revolutionizes scientific discovery by providing AI-powered tools and resources tailored to enhance scientific projects. By combining experimental tools from Google Labs with the scientific workflows available in Google Antigravity, it seeks to accelerate research efforts, enhance analytical capabilities, and empower researchers to explore the future of AI-driven scientific inquiry. The Literature Insights feature aggregates scholarly articles to identify new research opportunities, generate robust research outputs, and transform paper data into organized tables connected to original sources. Simultaneously, Hypothesis Generation utilizes a multi-agent strategy that mimics the scientific method, enabling it to identify gaps in knowledge, propose promising research paths, and outline testable research methodologies that have the potential to yield significant advancements. Furthermore, Computational Discovery aids researchers in pinpointing models and algorithms through a smart research engine that develops and assesses code variations based on user-defined optimization goals, thus further streamlining the research workflow. Overall, these cutting-edge tools are designed not just to enhance the efficiency of scientific research but also to fundamentally change the way it is perceived and executed. The integration of these advanced features signifies a major leap forward in the collaboration between AI and scientific exploration.

Biohub is a user-friendly platform focused on enhancing the comprehension of protein biology. It provides access to the ESM model family, which features ESMC, ESMFold2, and ESM3, as well as interactive tools and resources specifically designed for developers engaged in protein science research. ESMC is recognized as a state-of-the-art protein language model, carefully trained on extensive evolutionary sequence data, enabling it to generate representations that clarify fundamental mechanisms related to protein structure and function. This model supports a variety of applications, including functional analysis, structural predictions, protein design, and exploring evolutionary relationships among diverse proteins. In addition, ESMFold2 excels in predicting high-resolution, all-atom 3D structures of biomolecular complexes from sequences, and it allows for the incorporation of multiple sequence alignments to enhance accuracy for challenging targets. Furthermore, ESM3 adopts a comprehensive methodology by concurrently modeling sequence, structure, and function, which facilitates the innovative design of new proteins through a synergistic approach. This remarkable combination of tools and models equips researchers with the means to push the boundaries of protein science, fostering groundbreaking discoveries that could transform the field. Overall, Biohub's offerings represent a significant leap forward in our ability to manipulate and understand protein interactions and functionalities.

Everstar represents a cutting-edge AI-fueled solution designed to improve the implementation of nuclear energy by utilizing document intelligence, which includes support for licensing, regulatory workflow management, engineering analysis, and the automation of compliance procedures. Specifically designed for professionals in the nuclear sector, Everstar allows teams to convert complex documents into practical insights, facilitating the creation of regulatory-compliant filings, swift identification of pertinent precedents, reduction of siting durations, and enhancement of operational efficiency throughout the nuclear value chain, all while prioritizing safety. By harnessing advanced AI technology, Everstar effectively tackles significant administrative, regulatory, and engineering challenges within the industry, promoting accuracy, traceability, and secure operational processes. The platform is adaptable enough to meet the needs of a broad range of stakeholders, such as those engaged in reactor licensing, reactor management and engineering, approvals for new reactors, radioactive material handling, as well as supply chain and manufacturing sectors, along with regulatory agencies. This all-encompassing assistance encourages collaboration across various segments of the nuclear industry, leading to improved efficiency and heightened safety outcomes. As a result, Everstar not only streamlines complex tasks but also sets a new standard for operational excellence within the nuclear field.